Madrid

• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a … Recruiting
  2023-505436-35-00 5 2024-06-03 Untreated FLIPI 2-5 Follicular Lymphoma
• Open-label, single-arm, non-controlled trial to evaluate the safety and tolerability of treprostinil sodium in children below the age of 18 … Recruiting
  2023-505082-91-00 5 2024-05-29 Pulmonary Arterial Hypertension (PAH)
• A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet Recruiting
  2023-506150-21-00 4 2024-05-29 Celiac Disease
• A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un … Recruiting
  2023-508613-17-00 5 2024-05-29 Neoplasms, Head and Neck
• Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 … Recruiting
  2023-508808-38-00 1 2024-05-29 Solid tumors
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE) Recruiting
  2023-504251-27-00 7 2024-05-27 Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mut
• C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL … Recruiting
  2023-507871-23-00 5 2024-05-27 Relapsed/Refractory Multiple Myeloma
• A study of ASP3082 in adults with advanced solid tumors Recruiting
  2022-501590-39-00 1 2024-05-22 Solid Tumor
• A study of the efficacy and safety of belimumab compared to placebo in adults with systemic sclerosis-associated interstitial lung disease. Recruiting
  2023-503219-14-01 10 2024-05-22 systemic sclerosis associated interstitial lung disease
• A Single-Arm, Open-Label, Multicenter, Phase 1b/2 Study Evaluating the Safety and Efficacy of AUTO1 (obecabtagene autoleucel [obe-cel]) in P … Recruiting
  2023-506307-26-00 3 2024-05-22 B-cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-ce
• Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo … Recruiting
  2023-506308-24-00 10 2024-05-22 Recurrent or metastatic head and neck squamous cell carcinoma
• Clinical trial of trabectedin and low-dose radiation therapy in advanced/metastatic sarcomas Recruiting
  2023-509215-81-00 4 2024-05-22 Adult and young adult patients with diagnosis of advanced/metastatic s
• Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS- … Recruiting
  2023-505929-14-00 5 2024-05-21 Systemic Lupus Erythematosus
• An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study with Open-Label Extension Evalu … Recruiting
  2023-508818-42-00 10 2024-05-21 Generalized Epidermolysis Bullosa Simplex (EBS)
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants with Chronic Mye … Recruiting
  2023-507677-18-00 9 2024-05-17 Chronic Myeloid Leukemia
• Bevacizumab plus encorafenib-cetuximab in BRAF-V600E mutated metastatic colorectal cancer, a phase II study with a safety lead-in cohort, th … Recruiting
  2023-509204-15-00 4 2024-05-17 Metastatic colorectal cancer
• Fractionated stereotactic radiotherapy plus second-generation antiandrogen for oligometastatic patients with castration-resistant prostate c … Recruiting
  2023-505024-62-01 4 2024-05-16 Oligometastatic patients with castration-resistant prostate cancer
• CHOP PLUS MOSUNETUZUMAB AS FIRST LINE IN PATIENTS WITH RICHTER´S SYNDROME: A PHASE II STUDY OF THE SPANISH GROUP OF CLL (GELLC-9-RICHTER) Recruiting
  2023-505621-13-00 4 2024-05-14 Richter´syndrome
• Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy Recruiting
  2024-513601-31-00 4 2024-05-13 Acute lymphoid leukemia
• A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w … Recruiting
  2023-504151-27-00 5 2024-05-09 Psychosis associated with Alzheimer’s Disease
• Locally Advanced or Metastatic Hepatocellular Carcinoma: Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budiga … Recruiting
  2023-504600-28-00 10 2024-05-09 Metastatic Hepatocellular Carcinoma (HCC)
• First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma Recruiting
  2023-507213-97-00 1 2024-05-09 Relapsed/refractory B-cell aggressive lymphoma
• Phase II study of axitinib intensification plus standard of care (SOC) compared to SOC alone after induction with nivolumab plus ipilimumab … Recruiting
  2024-511397-70-00 4 2024-05-06 metastatic renal cell carcinoma (mRCC)

Showing 1,345–1,368 of 3,550 trials